Nominations now open — Submit before 15 December 2026 · Free to enterSubmit Now

The Remote Prescribing Question: Accountability in Telemedicine-Led Aesthetics

★
Editorial Team
DATENov 20, 2026
The Remote Prescribing Question: Accountability in Telemedicine-Led Aesthetics

A patient messages a clinic asking for a repeat neuromodulator appointment. They are travelling, cannot attend in person, and have been treated at the same clinic three times before. A practitioner offers a video call, confirms the request, and a prescription is issued to a pharmacy. The product is administered elsewhere, or by a colleague, or not at all. Each step feels reasonable in isolation. Taken together, they form a clinical pathway that few clinics have ever written down.

Remote consultation is now a normal part of aesthetic practice. Video calls are used for follow-ups, for triage, for pre-treatment screening and increasingly for the assessment that precedes a prescription. The technology is not the difficult part. The difficult part is that convenience has arrived faster than governance, and clinics that can describe their remote workflow in detail often cannot describe who is accountable within it.

For the Global Aesthetics Awards, this is likely to become a separating question. Entries that present telemedicine as an efficiency gain will read much like one another. Entries that can show a defensible model — defined scope, named responsibility, records that demonstrate the standard of care — will read differently.

Assessment, prescribing and delegation are three different acts

The first governance failure is linguistic. Clinics use "remote consultation" to cover several distinct activities that carry different risks and demand different records.

  • Remote assessment is the gathering of information at a distance: history, photographs, a conversation about concerns, prior treatment and medical factors.
  • Remote prescribing is a prescriber authorising a product without an in-person examination of the patient.
  • Delegated treatment is the administration of that product by a practitioner who may not be the prescriber and may not be in the same organisation.

Many clinics have adopted the first and assumed the second and third follow. A booking link for a video appointment is not a policy. The policy question is narrower and more uncomfortable: which products, at which doses, for which patients, may be authorised without an in-person examination, and who decided that.

Prescribing rules differ between jurisdictions and between product schedules, and a clinic that employs prescribers registered elsewhere, or treats patients who travel, may be working to more than one set of rules at once. That is an argument for a written scope rather than an informal understanding. A clinic that cannot state its own limits has not set any.

Who owns the patient when care is split

Complications do not arrive during the video call. They arrive later, often in the evening, and usually to the clinic the patient physically attended rather than to the prescriber they never met.

Split care is not inherently unsafe, but it only works when responsibility is assigned in advance. Clinics need explicit answers to a short list of questions. Who responds to an adverse event, and within what timeframe? Who holds the complete patient record, and how does the remote prescriber's assessment reach the treating practitioner? If the patient contacts the wrong party first, what happens? Who reviews the outcome afterwards?

Where these questions are unanswered, the default is improvisation at the worst possible moment. A patient with a vascular concern is passed between a clinic that administered the product and a prescriber who authorised it, while both assume the other is managing the situation.

Identity and history are harder to verify at a distance

Distance makes it easier to accept a patient's account at face value. In person, a practitioner observes the skin, the movement, the previous work. On a video call, they observe what the camera framing and the lighting allow, and the rest comes from the patient's description.

Clinics offering remote appointments should set a standard for what must be confirmed before a decision is made: that the patient is who they say they are, that prior treatments and products are recorded as far as they can be established, that relevant medical factors and previous adverse events have been asked about directly, and that any images used in the assessment are dated and attributable. Where something cannot be verified remotely, the record should say so and the pathway should account for it.

This is unglamorous work. It is also the difference between a remote service that can be defended and one that relies on the patient having been honest.

The record should show reasoning, not just the outcome

Most remote-care documentation records a decision. It notes that a video consultation took place and that treatment was approved. That is a log, not a clinical record.

A defensible record shows what was assessed, what was not, and why the remote route was considered appropriate for this patient at this point. It notes the alternatives considered and the circumstances that would have required an in-person review instead. It records who agreed to the plan and what the patient was told about the limits of a remote assessment.

If a patient later presents with an adverse event, the question asked of the clinic will not be whether the decision was convenient. It will be whether the standard of care was met. A record that demonstrates reasoning answers that question. A record that demonstrates only that a call happened does not.

Consent and indemnity need reviewing, not assuming

Consent for a telemedicine-led pathway should describe the remote element specifically: what the practitioner can and cannot assess at a distance, how the patient reaches someone if something goes wrong, and who that person is. A consent form written for in-person treatment rarely covers any of this.

Indemnity arrangements deserve the same scrutiny. Policy wording is not automatically drafted for remote prescribing, for cross-jurisdictional consultations or for delegated administration by a practitioner the prescriber has never met. Clinics that have added remote pathways should check what their cover actually describes rather than assume it follows the patient.

What a defensible model looks like

The clinics that handle this well tend to share the same features. They have a written scope for remote care that names the products and situations it covers. They assign responsibility for complications before a complication exists. They set identity and history standards for remote appointments. They document reasoning rather than outcome. And they have checked their consent and indemnity arrangements against the pathway they actually run.

None of this is a technology question. Remote consultation works; the platforms are reliable and patients accept them. The question is whether a clinic can explain, in writing and in advance, what it assesses at a distance, who is accountable when something goes wrong, and how its records would show that the standard of care was met.

That is the test award entries in this category will increasingly face. Convenience is easy to advertise and difficult to defend. Governance is the reverse, and it is the part worth demonstrating.